Royal Bank Of Canada Aptevo Therapeutics Inc. Transaction History

Royal Bank Of Canada

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	BUY	$1.74 - $2.54 $2,958 - $4,318	1,700 New	1,700 $3,000
Q2 2022 Aug 15, 2022	SELL	$3.26 - $6.3 $2,934 - $5,670	-900 Reduced 55.76%	714 $3,000
Q2 2021 Aug 16, 2021	BUY	$21.85 - $30.0 $35,265 - $48,420	1,614 New	1,614 $36,000

Ticker APVO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 5,090,640
Market Cap $24.5M
Description
Aptevo Therapeutics Inc., a clinical-stage biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. Its lead clinical candidate is APVO436, a bispecific T-cell engaging antibody candidate that is in Phase 1b clinical trial for acute myelogenous leukemia and myelo...

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

Stay updated on Royal Bank Of Canada with notifications on news.